-
Saturday charge has Young in sight of first major title at Masters
-
McIlroy looking for answers after squandered Masters lead
-
McIlroy and Young share lead after Masters third round
-
Lavelle marks 100th cap with goal in US win over Japan
-
Artemis crew urges unity on 'lifeboat' Earth
-
US, Iran talks extend into second day as strait showdown deepens
-
Former heavyweight king Fury outpoints Makhmudov, calls out Joshua
-
Former heavyweight king Fury outpoints Makhmudov on ring return
-
Two-time champ Scheffler surges up Masters leaderboard
-
McIlroy scrambles to hold off rivals and keep Masters lead
-
Milan's Serie A title hopes in tatters after shock Udinese defeat, Juve fourth
-
Easter truce between Russia and Ukraine falters
-
US warships transit Strait of Hormuz in mine clearance op
-
Playoff seedings on line as grueling NBA regular-season comes to close
-
Ngumoha's 'special' impact no surprise to Slot
-
Arsenal suffer major title blow as Liverpool earn vital win
-
US, Iran hold high-level peace talks in Pakistan
-
Over 200 arrested at pro-Palestinian rally in London
-
McIlroy tees off with six-stroke Masters lead
-
Record-breaking Bayern march closer to Bundesliga title
-
World champions England make winning start to Women's Six Nations
-
Yamal shines as Barca thrash Espanyol to extend Liga lead
-
Drean double sets Toulon up for Champions Cup semi against Leinster
-
Salah, Ngumoha ease Liverpool crisis with Fulham win
-
Arsenal suffer huge title blow as Liverpool earn vital win
-
Samson smashes hundred as Chennai notch first win of IPL season
-
Bayern Munich set Bundesliga record with 102nd goal of season
-
Milan's Serie A title hopes in tatters after shock Udinese defeat
-
Alcaraz and Sinner battle for No.1 spot in Monte Carlo final
-
In fiery speech, Pope Leo says 'Enough to war!'
-
Andreeva to face Potapova in Linz WTA final
-
Holders Italy, Britain into BJK Cup finals, USA knocked out
-
Arsenal suffer title 'punch' by Bournemouth, Everton hold Brentford
-
Drean double breaks Glasgow hearts as Toulon reach Champions Cup semis
-
Teen star Seixas seals Basque Tour triumph, August wins sixth stage
-
Scores arrested at pro-Palestinian rally in London
-
I Am Maximus emulates Red Rum to regain Grand National crown
-
Leverkusen sink Dortmund to bring Bayern closer to title
-
Planes fly from Beirut airport despite Israeli bombing
-
Pogacar dreaming of Monument clean-sweep
-
Arteta urges Arsenal to stand up after 'punch in the face'
-
Iyer leads Punjab's chase of 220 to down Hyderabad
-
Arsenal defeat blows Premier League title race wide open
-
Buffets, baristas, but no briefings: journalists frozen out of Iran talks
-
McIlroy's Masterpiece remains the buzz at Augusta
-
Sinner brushes past Zverev to reach Monte Carlo final
-
Arsenal suffer major blow in Premier League title charge
-
UK puts Chagos handover deal in 'deep freeze' after Trump criticism
-
In Europe first, Netherlands to allow Teslas to self-drive
-
Sabrina Carpenter transforms Coachella into her own 'Sabrinawood'
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
Ch.Campbell--AT